Tag: 652 nm

ML7710 for photoactivated treatment of lung cancer

Deadliest cancer Precision with photoactivation Photoimmunotherapy with ML7710 offers a clinical therapeutic option for NSCLC patients even with advanced disease stage. Besides laser light, this therapy involves photoactivated drug, which can be activated precisely at the tumor site with laser fibers, hence minimizing drug effects to healthy tissues. Smaller invasiveness compared to surgery can enable […]

ML7710 for photoactivated treatment of lung cancer Read More »

Light-based enhancement of vaccination in humans

Application Note / 652 nm, bile duct cancer, HPV16, human papilloma virus, ML7710, PCI, PCI Biotech, T-cell response, vaccination, vaccine

Motivation Vaccines should activate all branches of immunity, including T cells and antibody responses, for generating a strong immune response. For therapeutic cancer vaccines, it is especially important to induce strong cytotoxic T-cell responses, since cytotoxic T-cells are the most potent immune cells for killing cancer cells. While cytotoxic T-cells can often be induced

Light-based enhancement of vaccination in humans Read More »

Disulfonated tetraphenyl chlorin (TPCS2a)-induced photochemical internalisation of bleomycin in patients with solid malignancies: a phase 1, dose-escalation, first-in-man trial

Scientific papers / 652 nm, clinical, H&N cancer, head & neck cancer, ML7710, Phase 1, Photochemical internalisation, TPCS2a

Published in: Lancet Oncology Authors: Ahmed A Sultan, Waseem Jerjes, Kristian Berg, Anders Høgset, Charles A Mosse, Rifat Hamoudi, Zaid Hamdoon, Celia Simeon, Dawn Carnell, Martin Forster, Colin Hopper

Disulfonated tetraphenyl chlorin (TPCS2a)-induced photochemical internalisation of bleomycin in patients with solid malignancies: a phase 1, dose-escalation, first-in-man trial Read More »